← Back to Clinical Trials
Recruiting NCT06442319

NCT06442319 The Efficiency and Safety of PRP Treatment After Anterior Cruciate Ligament Reconstruction.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06442319
Status Recruiting
Phase
Sponsor Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz
Condition ACL Injury
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-06-01
Primary Completion 2028-04-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Platelet-rich plasma

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-06-01 with a primary completion date of 2028-04-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The anterior cruciate ligament (ACL) is the main stabilizer of the knee joint, as it controls anteroposterior and rotatory knee laxity. The number of ACL injuries has increased in the past three decades because more and more people participate in recreational and competitive sporting activities. Injury to the ACL often leads to functional instability, damage to the meniscus and articular cartilage, and an increased risk for osteoarthritis (OA). Emphasizes the fact that ACL has limited healing potential 'The gold standard' treatment is ACL reconstruction, with over 200,000 reconstruction surgeries performed annually in the United States. However, despite the success of surgery in restoring functional stability, it has been found so far in several studies that the prevalence of moderate to severe arthritis in long-term radiographic follow-up is more than 50% after ACL reconstruction within 5 to 15 years or sooner. ACL-injured knees had at least 3 times higher risk of arthritis than uninjured contralateral knees. Early osteoarthritis was observed on magnetic resonance imaging (MRI) up to 11 years following ACL injury after operative and nonoperative management. Because ACL injuries predominantly occur in individuals between the ages of 15 and 25 years, symptoms of OA most often affect patients during their most productive years. This is worrisome because most patients who sustain ACL tears are free of the risk of other factors for developing OA.Consequently, posttraumatic OA after ACL reconstruction ultimately translates into a large economic effect on the healthcare system owing to the young age of this population. Platelet-rich plasma is an autologous solution of highly concentrated platelets dispersed in a small capacity of plasma. Enthusiasm for the therapeutic potential of platelets is based on its rich omplement of anabolic growth factors and anti-inflammatory cytokines in the platelets, which induce cellular proliferation, migration, differentiation, angiogenesis, and extracellular matrix synthesis. In addition, the functional mechanisms of PRP in OA treatment have been explained by its effect on modulating critical pro-inflammatory mediators and catabolic enzymes, as well as maintaining joint homeostasis. The reasons for this early incidence of post-traumatic OA remain unclear, but the underlying mechanisms have been speculated to involve some combination of cartilage damage at the time of injury, and posttraumatic molecular changes in the joint, including immune reactions or persistent secondary inflammation. We hypothesized that PRP injection after ACL reconstruction could prevent cartilage damage, act anti-inflammatory, and provide better clinical and radiological outcomes seen in MRI.

Eligibility Criteria

Inclusion Criteria: * subject is 18-45 years old * subject has BMI \< 40 kg/m2 * subject had ACL reconstrution * small asymptomatic meniscal lesions that won't require repair * subject must be willing to abstain from other intra-articular treatments of the knee for the duration of the study. * subject is willing to discontinue all analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs), except tramadol and paracetamol, at least one month before the synovial fluid aspiration and through the completion of the study * subject is able to understand and comply with the requirements of the study and voluntarily provides consent Exclusion Criteria: * subject has a history of metabolic diseases, endocrine disorders, rheumatic and connective tissue diseases, cancer, hormonal contraception, steroid therapy, antibiotic therapy * subject had an intraarticular injection into the affected joint * subject had previous operations (beside ACL reconstruction) or fractures of the affected limb * subject has a history of nicotine, alcohol, or drug addiction * subject has a meniscal tear that requires suturing or total meniscectomy seen on MRI * subject has multi-ligament knee injuries or multi-organ injury * subject has significant varus or valgus deformity greater than 10 degrees in either knee, determined by an X-ray

Contact & Investigator

Central Contact

Dawid Szwedowski, MD, PhD

✉ dszwedow@yahoo.com

📞 608075237

Frequently Asked Questions

Who can join the NCT06442319 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying ACL Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06442319 currently recruiting?

Yes, NCT06442319 is actively recruiting participants. Contact the research team at dszwedow@yahoo.com for enrollment information.

Where is the NCT06442319 trial being conducted?

This trial is being conducted at Torun, Poland.

Who is sponsoring the NCT06442319 clinical trial?

NCT06442319 is sponsored by Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology